DDInter703 DDInter1676
Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Etravirine {u} (Compound) binds {v} (Gene) ABCB1
Etravirine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Analog
Etravirine {u} (Compound) causes {v} (Side Effect) Disturbance in attention
Etravirine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Etravirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Etravirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Etravirine {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Etravirine {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Etravirine (Compound) resembles Rilpivirine (Compound)
Etravirine (Compound) binds ABCB1 (Gene)
Etravirine (Compound) is included by Non-Nucleoside Analog (Pharmacologic Class)
Etravirine (Compound) causes Disturbance in attention (Side Effect)
Etravirine may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Etravirine may lead to a major life threatening interaction when taken with Encorafenib
Etravirine may lead to a major life threatening interaction when taken with Cobimetinib